The chemokine receptor CXCR4 favors the interaction of acute myeloid leukemia (AML) cells with their niche but the extent to which it participates in pathogenesis is unclear. Here, we show that CXCR4 expression at the surface of leukemic cells allowed distinguishing CXCR4
CXCL12 stimulates integrin activity, favoring HSPC interaction with their microenvironment. 8, 9 Hence, CXCL12/CXCR4 signaling has a critical role in the retention of HSPC in BM niches. 10, 11 Besides this pro-adhesive activity, CXCL12/ CXCR4 may directly regulate HSPC proliferation, survival and differentiation. 12, 13 Recently, several small molecule competitive antagonists of CXCR4 have been described, of which AMD3100 has been administrated to human subjects.
These inhibitors antagonize CXCL12 binding to CXCR4, disrupt CXCL12-mediated chemotaxis and induce mobilization of HSPC into peripheral blood. [14] [15] [16] [17] Acute myeloid leukemia (AML) represents a heterogeneous group of hematopoietic malignancies with various morphological features, genomic abnormalities and clinical manifestations. Despite this heterogeneity, many primary AML retain a number of characteristics of normal hematopoiesis including a cell hierarchy organization. 18, 19 This includes the presence of a small subset of AML cells, referred to as SCID-LICs (leukemia-initiating cells) or leukemic stem cells, at the top of this hierarchy, which perpetuates the disease. 18, [20] [21] [22] Although characterized by uncontrolled growth and survival advantage, most primary AML cells retain dependency on BM microenvironment or niches, which might be their Achilles' heel. 23 However, leukemic cells are often found in extramedullary sites, suggesting that permissive niches may also exist in other sites. 24, 25 Similarly to its role in normal hematopoiesis, the CXCR4/CXCL12 axis also acts as a critical regulator of AML biology 26 and high CXCR4 membrane expression on leukemic blasts correlates with a poor prognosis. 27, 28 Accordingly, a therapeutic effect of CXCR4 antagonist Plerixafor (AMD3100) is observed when used in combination with chemotherapy or FLT3 inhibitors in mice bearing human and murine AML cell lines or in murine genetic model of acute pro-myelocytic leukemia. 29, 30 Moreover, the addition of Plerixafor to cytotoxic chemotherapy in a phase 1/2 study resulted in encouraging rates of remission. 31 However, the biological effects of these antagonists on primary human AML cells when used alone in vivo remain to be investigated.
Here, we identified two groups of AML patients according to their CXCR4 membrane expression and CXCL12-mediated chemotaxis and report for the first time that the use of CXCR4 antagonists, AMD3100 and TN140 alone selectively induced leukemia regression when AML cells originally expressed high CXCR4 levels and displayed significant migratory response to CXCL12. Thus, this work represents a proof of concept that CXCR4 inhibition, as a single agent, may be a therapeutic approach in selected patients.
Results
CXCR4 expression and response to CXCL12 are intrinsic features of AML cells. We evaluated the level of CXCR4 membrane expression on leukemic blasts of 47 AML samples that encompassed a broad range of disease subtypes and treatment outcomes. Of 47 samples evaluated, 22 displayed mean fluorescence intensity ratios (MFIRs) below 5 (CXCR4 neg/low ), whereas 25 displayed MFIRs higher than 5 (CXCR4 high ). For three patients, CXCR4 expression was evaluated on both peripheral and BM samples and no difference in expression was observed (data not shown). The chemotactic response to CXCL12 was analyzed on 41 out of 47 AML samples. The median percentage of cells that had migrated in the presence of CXCL12 was 15%, which exceeded the comparative 2.6% value in medium alone (Po0.01). Correlation analysis revealed a statistically significant correlation between chemotaxis and the overall CXCR4 expression (Supplementary Figure 1, Figure 2) . For each specimen, CXCR4 membrane expression was similar before and after engraftment (Figure 1a ). CXCL12-induced migration of the eight individual AML samples was also evaluated before and after engraftment. Before transplantation, spontaneous migration (medium alone) of patient cells ranged between 1.3 and 5%, whereas in response to CXCL12 (specific migration) values ranged from 3 to 30%. Among them, four had CXCL12-induced migration close to spontaneous migration indicating weak or even no CXCL12 responsiveness, whereas the four others had significant response to CXCL12 (Figure 1b) . After transplantation, spontaneous migration of human cells isolated from the mouse BM ranged between 2.5 and 9.6%, whereas specific migration values ranged from 6.4 to 46.8%. Concordant results were obtained between BM and spleen-derived cells for the two patients analyzed (not depicted). For each specimen, CXCL12 response was not significantly different before and after transplantation and non-responders remained non-responders after engraftment (Figure 1b) . Therefore, CXCR4 membrane expression and CXCL12 responsiveness represent an intrinsic feature of individual leukemia that is not modified by engraftment and by the NOD/Shi-scid/IL-2Rg null (NOG) mouse microenvironment. Figure 1 Comparison of CXCR4 expression levels and chemotaxis responses to CXCL12 before and after engraftment. (a) CXCR4 membrane expression levels on AML blasts from patients (black dot) and human leukemic cells isolated from the BM of NOG mice (white triangle) 16 weeks post engraftment. The horizontal line (MFIRs ¼ 5) indicates the threshold used for stratification. (b) Spontaneous (white dot and white triangle) and specific migration to 100 ng/ml CXCL12 (black dot and black triangle) of AML blasts from patients (black and white dot) and human leukemic cells isolated from the BM of NOG mice (black and white triangle) 16 weeks post engraftment. The horizontal line shows the highest spontaneous migration ratio (9.6%) CXCR4 inhibitors induce regression of CXCR4-expressing AMLs and targeted LICs in the BM. The effects of CXCR4 inhibitors in vivo were determined on leukemic mice generated from these eight samples. Taking into consideration the short in vivo half-life of AMD3100 (3-5 h) 32 and TN140 (9.6 h), 33 the drugs were administered by s.c. pumps implantation during 7 days. Administration of TN140 or AMD3100 to a lesser extent resulted in a marked decrease in anti-CXCR4 antibody 12G5 binding to AML cells isolated from blood, BM and spleen from mice engrafted with CXCR4 high cells, while binding was minimally changed in mice engrafted with CXCR4 neg/low cells (Figure 2a ). This indicates that TN140 or AMD3100 functionally blocks CXCR4 as the 12G5 antibody identifies the epitope involved in CXCL12 binding. The in vitro migration response to CXCL12 of AML cells isolated from the mouse BM was sharply inhibited by TN140. A much more moderate effect was observed with AMD3100 ( Figure 2b ), indicating differential efficacy between these two inhibitors.
BM cells were counted and the percentage of human CD45 þ CD33 þ cells was determined upon 7 day treatment. In four cases (#7 with AMD3100 and TN40; #15, #18 and #14 with TN140), corresponding to those with higher CXCR4 expression and higher CXCL12 chemotaxis, the total number of leukemic cells was significantly reduced in the BM of treated mice compared with control mice (Figure 3a) . For patients 7 and 18, mice treated with TN140 for 7 days demonstrated prolonged overall survival compared with control mice (Figure 3b ). AMD3100 administration only moderately increased the survival of treated mice. For patients 7 and 12, corresponding to those with lower CXCR4 expression and lower CXCL12 chemotaxis, only a small relative effect of CXCR4 inhibitors was observed.
To test if the CXCR4 inhibitors targeted the LICs, CD45 þ cells were sorted from the BM of PBS-, AMD3100-or TN140-treated mice engrafted with AML cells (#7 and #18) and transplanted into secondary hosts. Eight weeks after secondary transplantation, the presence of human myeloid cells (CD45 þ CD33 þ CD19 À ) was assessed in the blood. Figure 3c represents the percentage of human cells observed in secondary recipients reconstituted with the BM cells of treated or untreated mice (obtained in Figure 3a) and indicated that the percentage of circulating human cells was much lower in mice transplanted with cells sorted from TN140-or AMD3100-treated mice than in control mice. In addition, overall survival of the secondary recipients demonstrated higher survival compared with controls, indicating that LICs were targeted by TN140 and AMD3100 to a lesser extent (Figure 3d ).
CXCR4 inhibitors induce regression of CXCR4-expressing AMLs in the mouse tissues. Immunohistological analyses of xenografted mice revealed the presence of large clusters of AML CD45 þ cells surrounding the bile ducts and along the larger venous in the CXCR4 high group, in addition to isolated cells in sinusoids scattered throughout the parenchyma. In the CXCR4 neg/low group, AML cells appeared to be distributed more homogeneously throughout the parenchyma with small clusters along the large venous (Figure 4a ). To understand whether the organ infiltration was related to CXCL12, we tested CXCL12 mRNA expression in the hematopoietic organs of normal NOG mice. CXCL12 mRNA expression was detected in BM and spleen cells, whereas it was undetectable in blood cells (Figure 4b ). CXCL12 protein was detected at a high level in BM supernatant and plasma, and at a lower extent in spleen and liver supernatants (Figure 4c ). In liver, CXCL12 was concentrated in the bile duct epithelial cells, as detected by the immunohistochemistry (Figure 4d ). These findings indicate that expression of CXCR4 may permit redistribution of AML cells toward CXCL12 synthesizing cells in the liver, suggesting that the dissemination of cells expressing CXCR4 is not random, but might be guided by CXCL12 production in specific sites.
In spleen, leukemic cell number was reduced by AMD3100 and TN140 (#7 and #14) or TN140 only (#15 and #18) ( Figure 4e ). In liver, TN140 and AMD3100 more modestly decreased the number of human CD45 þ cells infiltrating the sinus or located along the big venous and bile ducts ( Figures   Figure 2 In vivo administration of CXCR4 inhibitors reduces CXCR4 membrane expression and migratory capacity of leukemic cells. NOG mice were engrafted with AML cells from patients indicated below horizontal axis. Twelve to sixteen weeks post transplant, PBS (black diamond), AMD3100 (gray circle) or TN140 (white triangle) was administered s.c. using Alzet osmotic pumps during 7 days. (a) Membrane CXCR4 expression levels on human leukemic cells in blood, BM and spleens by flow cytometry. Each point is the average MFI of CXCR4 for human cells recovered from 4 to 6 mice engrafted with cells from the same patient. (b) Transwell migration of human cells recovered from BM of PBS-and inhibitor-treated mice in response to 100 ng/ml CXCL12. Each point is the average migration ratio from four mice 4f-h). Thus, CXCR4 inhibitors induced leukemic regression in the BM, spleen and liver of mice engrafted with AML cells that expressed higher CXCR4 at their surface or exhibited higher CXCL12 chemotaxis, suggesting that CXCR4 expression level and migratory response to CXCL12 may predict CXCR4 inhibitor efficacy.
CXCR4 inhibitors induced rapid mobilization of AML cells in NOG mice. We studied whether disruption of the CXCR4/CXCL12 axis would disturb the homing of leukemic cells. AML cells were treated or not in vitro with CXCR4 inhibitors, labeled by CSFE and i.v. injected into secondary hosts. No significant difference was observed in the (Figure 5b ). In addition, no difference in the leukemic reconstitution was observed among recipients who received PBS-or inhibitor-treated cells (Figure 5c ), suggesting that CXCR4 inhibitors did not alter homing capacity of LICs.
To further explore the mechanism of the leukemic regression induced by CXCR4 inhibitors, we evaluated the potential of CXCR4 inhibitors to mobilize AML cells. Leukemic mice were treated with the inhibitors for 24 h, blood was collected and analyzed for CD45 þ cell numbers. In all but one case (#13), the number of human cells was significantly increased in the blood of TN140-treated mice compared with controls. AMD3100 also resulted in a significant increase in human cell numbers except for one case (#12) (Figure 6a ). Leukemic progenitor cells circulating in blood were evaluated by methylcellulose colony assays. In all cases but one (#12) treated with AMD3100, their number was significantly augmented (Figure 6b ). Secondary transplantation of blood from treated and untreated animals showed that LICs were also mobilized to the circulation (Figure 6c ). These results and those showing a decrease in leukemic cell numbers in the BM of treated mice (Figure 3c ) indicate that CXCR4 inhibition is associated with a mobilization of leukemic cells from the BM to blood.
To document the mobilizing effects of leukemic cells by CXCR4 inhibitors, experiments were performed after one acute subcutaneous injection of AMD3100 or TN140. Three hours after injection, spleens and livers of treated mice recover the red color of normal spleens and livers (Figure 7a) . A significant increase in the number of leukemic cells measured in the blood of the treated was also observed, suggesting a rapid decrease in the white cell infiltration in these organs (Figure 7b ). CXCR4/CXCL12 has been shown to trigger AKT and ERK signaling, which may account for the survival advantage conferred by CXCL12. 34, 35 We observed a marked decrease in ERK phosphorylation and to a less extent in AKT phosphorylation in leukemic cells recovered from the BM and spleen of AM3100-or TN140-treated mice. Increased levels of active cleaved caspase-3 were also seen in the BM and spleen cells recovered from inhibitor-treated mice (Figure 7c) . Altogether, these results indicate that CXCR4/ CXCL12 axis has a pivotal role in the retention of leukemic cells in BM as well as in extramedullary sites. Disruption of the interaction of leukemic cells with their microenvironment may promote their apoptosis and leukemia regression.
CXCR4 inhibitors disrupt adhesion of AML cells with stromal cells and induce their apoptosis in vitro. To understand the role of CXCR4 inhibitors, we performed in vitro experiments co-culturing CXCR4-expressing AML cells with stromal cells or CXCL12. The two drugs decreased the adhesion of AML cells to CXCL12-producing MS-5 stromal cells (Figures 8a and b) . In addition, in the absence of CXCL12 or stromal cells, a basal level of spontaneous apoptosis of AML cells was observed. This spontaneous apoptosis was not modified by AMD3100 or TN140 treatment (Figure 8c ). Addition of CXCL12 in the medium or co-culture with MS-5 cells decreased the spontaneous apoptosis, an effect that was partially overcome by AMD3100 and, more importantly, by TN140 (Figure 8c) . Thus, adhesion to stromal cells protects AML cells from spontaneous apoptosis and 
Discussion
The present study demonstrates in a mouse xenograft model that, when high levels of CXCR4 are expressed at the surface of AML cells, blocking the receptor function with small molecule inhibitors can promote leukemic cell death and reduce LICs. Conversely, these drugs have no efficacy when AML cells do not express CXCR4 or when they do not respond to CXCL12. Therefore, CXCR4 expression level on AML blast cells and their migratory response to CXCL12 are predictive of the response to the inhibitors, hence could be used as biomarkers to select patients that could potentially benefit from the drug. Since one of the tested CXCR4 antagonists has been approved for clinical therapy, such treatment could be rapidly evaluated in the treatment of CXCR4-positive AMLs.
Previous studies showed that AMD3100 or its analog AMD3465 enhanced the anti-leukemic effects of chemotherapy or that of the FLT3 inhibitors and resulted in markedly reduced leukemic burden and improved overall survival. 29, 30 These finding indicate that CXCL12/CXCR4 interactions contribute to the resistance of leukemic cells to signal transduction inhibitor-and chemotherapy-induced apoptosis. In our study, we used CXCR4 inhibitors as single agent and choose to use the xenotransplantation mouse model based on the NOG immunodeficient mice transplanted with primary patient cells.
The characteristics of the leukemia developed by each set of mice varied from patient to patient and xenotransplanted cells retained the fundamental biological characteristics of the original disease including the patient-specific pattern of CXCR4 expression and CXCL12-mediated chemotaxis. This indicates that these properties are modified neither by the xenotransplantation process nor by the murine microenvironment and likely depend on the particular genetic alterations present in the leukemic clone. Thus, transplantation of patient AMD3100, which has been approved for clinical use, is currently used for HSPC mobilization in the transplantation setting and is a well-tolerated drug. 36 TN140, a small peptide inhibitor that appears to be more efficient than AMD3100 in all our CXCR4
high AML models, is not approved for clinical use so far. The two inhibitors were administered by continuous subcutaneous infusion for 1 week in leukemic mice generated with primary cells from eight AML patients. Both and more strikingly TN140 induced an obvious reduction of BM leukemic cell number in four out of these eight cases. Importantly, three of the four responding cases belonged to the CXCR4 high group and the remaining one (#14) had the highest CXCR4 expression in the CXCR4 neg/low group. Importantly, this patient exhibits a CXCL12 migratory response similar to those of CXCR4 high group in contrast to the four resistant cases that showed minimal response to CXCL12-mediated chemotaxis, indicating that CXCL12 chemotactic response is not strictly linked to CXCR4 expression. These results may be related to the multiple mechanisms that regulate CXCR4 membrane expression including cell surface trafficking and cleavage by proteolytic enzymes. [37] [38] [39] Indeed, it was shown that AML cells express cytoplasmic CXCR4. 40 These results imply that CXCR4 expression combined with efficient CXCL12 chemotactic responses may provides a powerful test to define responders to CXCR4 antagonist therapy. In addition, the four resistant cases showed minimal response to CXCL12-mediated chemotaxis, suggesting that the effect of AMD3100 and TN140 on the responding leukemia may be mediated by a direct inhibition of the CXCR4 receptor in vivo. A similar reduction in leukemia burden was observed with a neutralizing CXCR4 antibody in a xenograft model using primary human leukemic cells. 40 However, in this study, no predictor of the drug activity has been identified.
High CXCR4 expression has been associated with the development of a more aggressive phenotype with an increased extramedullary organ infiltration in patients with acute lymphoid leukemia. 41 When the distribution of engrafted AML cells in the NOG mice was analyzed in our series, we observed that leukemic cells from CXCR4 high patients displayed specific localization in the mouse liver, which corresponds to the site of CXCL12 production, whereas the distribution of CXCR4 neg/low cells in the liver was diffuse. CXCR4 antagonists induced a sharp decrease in CXCR4 high leukemic cells in the BM, in the spleen and in the liver.
The mechanism of action of the two tested CXCR4 antagonists in AML is only partly understood. First, we showed that chronic or acute administration of these drugs results in a rapid mobilization of bulk leukemic cells and progenitors into the blood. To evaluate if the CXCR4 inhibitors targeted the LICs, we used a surrogate assay the capacity of a given sample to be xenografted. We preferred to measure the biological properties of LIC than to determine LIC-linked surface markers because previous studies have shown that there is considerable intersubject heterogeneity in LICaffiliated cell surface markers and an inability to apply them universally. 42 Results showed that LICs were also mobilized in the blood, which is consistent with the role of CXCR4 in the retention of normal HSPC in the BM and the mobilizing effect of AMD3100 and TN140.
In a recent study, in AML patients, it was also shown that AMD3100 administered with chemotherapy induced a 2-fold mobilization in leukemic blasts. Thus, these drugs may disrupt the interaction of leukemic cells with their supportive niches. This is further demonstrated by in vitro experiments, in which CXCR4 antagonists decreased adhesion of leukemic cells to stromal cells, which promotes their death by apoptosis. Most importantly, CXCR4 antagonists prolonged the survival of treated mice and TN140 markedly decreased the capacities of BM leukemic cells to give leukemia after secondary transplantation underscoring that CXCR4 antagonists target LICs. These inhibitors could therefore be tested either in combination with initial chemotherapy or to eradicate residual disease after remission obtained with conventional treatment to decrease the risk of relapse. Of course, it will be important to understand its possible toxicity of long-term administration in advance since it is known that chronic administration of AMD3100 maybe toxic in HIV patients.
Of note, the mobilization effect of CXCR4 antagonists was not limited to CXCR4 high cases, suggesting that blockage of CXCR4 is not the unique reason for AML cell mobilization. Alteration of hematopoietic microenvironment by CXCR4 inhibitors has been reported previously and may account for AML mobilization. 43 In our hands, the TN140 inhibitor appears to be more efficient than AM3100. This may be related to relative longer half-life of TN140 or to its higher affinity to CXCR4. However, both AMD3100 and TN140 induced efficient mobilization of AML cells to the circulation, suggesting that both drugs are capable of 'priming' AML cells to enhance sensitivity to chemotherapy in both CXCR4 high and CXCR4 neg/low patients. In summary, our study identifies two groups of AMLs according to their positive or negative response to CXCR4 inhibitors, and demonstrates that CXCR4 blocking agents effectively antagonize CXCL12-promoted leukemic development in selected patients characterized by high CXCR4 expression and CXCL12 migratory response. Since overexpression of CXCR4 and engraftment in immunodeficient mice are two poor prognostic factors in AMLs, the ability of CXCR4 antagonists to improve the clinical results in this disease now deserves to be tested. As this study suggests an effect on LICs, this anti-CXCR4 therapy might be interesting not only to modulate the effect of chemotherapy, but also to target residual LICs after remission to avoid relapse Mice. NOG mice were bred and maintained under specific pathogen-free conditions at the animal facility of Gustave Roussy Institute. Animal experiments were performed in accordance with guidelines established by the Institutional Animal Committee.
CXCR4 expression analysis. Mononuclear cells were triple-stained with an APC-conjugated anti-CD34 mAb, an FITC-conjugated anti-human CD45 mAb and a PE-conjugated anti-CXCR4 mAb (12G5). Appropriate Ig isotypes were used as controls. All antibodies were from BD Pharmingen (Le Pont De Claix, France). Quantitative analyses of fluorescence intensity were performed on gated CD45 low and/or CD34 þ cells and the mean fluorescence intensity (MFI) was calculated. MFIRs were calculated by dividing the MFI for CXCR4 by the MFI of the respective non-specific isotype control. To analyze CXCR4 expression level on human cell populations proliferating in the NOG mouse, a PE/Cy7-conjugated rat anti-mouse CD45 mAb was used in addition to the three mAbs mentioned above. MFI of CXCR4 was calculated on the gated human CD45 þ population.
Chemotaxis assay. Migration assays were performed with 5 mm-pore filters chambers (Transwell, ThinCert 24-well Translucent RoTrac; Greiner Bio-one, Courtaboeuf, France) as previously described. 44 To evaluate the migratory capacity of the human leukemic cells isolated from the BM of engrafted mice, a rat anti-mouse CD45 mAb was used to distinguish murine and human cells. All assays were done in triplicate. 
þ population was considered as AML engraftment. 33 The number of human leukemic cells was calculated by the equation: total cell number Â % of human CD45
þ CD33 þ cells.
Treatment with CXCR4 inhibitors. AMD3100 (Sigma-Aldrich, Saint Quentin Fallavier, France) (20 mg/kg/day) and TN140 33 (24 mg/kg/day) were administered s.c. by Alzet osmotic pump (Durect Corporation, Cupertino, CA, USA). Control animals received pumps containing PBS. After 7 days, blood, BM and spleens were analyzed for total cell numbers and the presence of leukemic cells by flow cytometry. For short assays, AMD3100 (200 mg/mouse) or TN140 (100 mg/mouse) was given in a single s.c. injection and mice were killed 3 h later.
Secondary transplantation. For secondary transplantation performed with BM cells, one femur and two tibias were flushed in 1 ml PBS. In all, 100 ml was i.v. injected into irradiated mice. For secondary transplantation with blood, 200 ml of blood was recovered 24 h after treatment and nucleated cells were injected into irradiated recipients. Human cells engraftment was assessed 8 weeks later.
Assessment of human hematopoietic clonogenic progenitors. Fifty microliters of blood from mice was lysed and plated in human complete methylcellulose medium and scored at day 14 as previously described. 45 Histopathology and immunohistochemistry. Deparaffinized liver sections processed for heat-induced antigen retrieval were incubated with a mouse anti-human CD45 mAb (Dako, Trappes, France) or a rabbit polyclonal anti-CXCL12 antibody (eBioscience, Paris, France). Staining was visualized by Histomouse Kit (Zymed, South San Francisco, CA, USA) or Rabbit PowerVision kit (ImmunoVision Technologies, Hillsborough, CA, USA). The sections were counterstained with hematoxylin and examined by a Zeiss Axiophot microscope (Carl Zeiss, Le Pecq, France). Whole sections of liver were scanned (Nikon, Val de Marne, France) and adobe photoshop software was used to calculate the total tissue area and the area of positive immunostaining. CXCL12 measurements. Plasma was prepared from the citrated blood. One femur and two tibias were flushed in 1 ml of PBS. Spleen and liver were crushed in 2 ml PBS, respectively. CXCL12 levels in the supernatant and plasma were evaluated by an ELISA system (R&D Systems, Lille, France).
Homing assay. Leukemic cells (20 Â 10 6 ) from BM of reconstituted mice were stained with 1 mM 5(6) carboxyfluorescein diacetate N-succinimidyl ester (CFSE; Sigma-Aldrich). Just prior intravenous injection into irradiated mice, cells were incubated for 30 min at 371C either with PBS or with AMD3100 (20 mM) or TN140 (5 mM). Three hours after injection, cells were recovered from the blood, BM and spleen and analyzed by FACSort cytometry to determine the percentage of CFSE bright cells. To verify the homing capacity of LICs, a low dose (0.1 Â 10 6 ) of cells treated as above were inoculated into irradiated mice. The presence of human cells in the mouse BM was evaluated 8 weeks later.
Adhesion and apoptosis assay. Cells pre-incubated in the medium alone or with AMD3100 20 mM or TN140 5 mM at 371C for 30 min were seeded on the top of MS-5 stromal cells supplemented with the inhibitors at the same concentration. Non-adherent and adherent cells were separately collected 24 h later and labeled with anti-human CD45 mAb followed by counting on flow cytometry. Non-adherent and adherent cell numbers were calculated on the gated human CD45 þ population. For the cell viability assays, pre-incubation of AML cells without or with inhibitors was done as above. Without washing, cells were seeded in the medium alone or medium supplemented with CXCL12 100 ng/ml or on the top of MS-5 stromal cells. Twenty-four hours later, non-adherent cells were labeled with anti-human CD45 mAb and processed to FITC conjugated-annexin V labeling (BD Pharmingen). The percentage of apoptotic cells was calculated on the gated human CD45 þ population by flow cytometry.
Immunoblotting. Cells were lysed in ice-cold lysis buffer (NP-40 1%, HEPES 20 mM, KCl 10 mM, EDTA 1 mM, Glycerol 10%, protease inhibitors cocktail Complete (Roche, Meylan, France)). Protein was separated on polyacrylamide gel electrophoresis (Invitrogen, Saint Aubin, France) and transferred onto PVDF membranes. The following primary antibodies were used: anti-caspase 3, antiphospho ERK, anti-ERK, anti-phospho Akt, anti-Akt (Cell Signaling, Danvers, MA, USA). Proteins were visualized with horseradish peroxidase-conjugated secondary antibody and chemoluminescent substrate on CL-Xposure films (Pierce, Thermo Scientific, Illkirch, France). Anti-actin (AbCys, Paris, France) antibody was used to control equal loading.
Statistics. Data are reported as the mean±S.D. Differences in the distribution of continuous variables between categories were analyzed by Mann-Whitney test and Student's t-test. The BiostaTGV (http://marne.u707.jussieu.fr/biostatgv) statistical package was used for these calculations. For survival analysis, the Kaplan-Meier method of R software was used (http://www.r-project.org/). The logrank test was used to check for equality of the survival distributions. In all evaluation, differences were considered as significant if the P-value was o0.05.
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